Virax Biolabs Group annual ebitda
2024
2025
Virax Biolabs Group EBITDA Growth & History (VRAX)
Virax Biolabs Group's calculated EBITDA was −$5.9M for fiscal 2025.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-03-31 | −$5.9M | $545,307 | — |
| 2024 | 2024-03-31 | −$6.4M | — | — |
Virax Biolabs Group quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Virax Biolabs Group ebitda trends
Across the available reported history, Virax Biolabs Group's ebitda increased from −$6.4M to −$5.9M, a change of $545,307.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group filings at SEC.gov ↗